Pamplona Biotechnology

Pamplona Biotechnology is an early-stage drug discovery company specializing in targeted protein degradation (TPD) therapies for autoimmune and oncology diseases. The company leverages its proprietary AI-driven platform, ASTRIDE® (AI-driven Structure-based TPD Rational Design Platform), which integrates target structure prediction, high-throughput virtual screening, and ubiquitination assessment to accelerate the development of novel medicines. Pamplona has successfully advanced its lead autoimmune-focused program to clinical stages, receiving IND clearance from both the FDA and Chinese regulatory authorities. The company also collaborates with partners like Coherent Biopharma to develop next-generation degrader-conjugate therapeutics, aiming to address undruggable targets and significant unmet medical needs.